Literature DB >> 30505850

Finite Element Analysis of the Mouse Distal Femur with Tumor Burden in Response to Knee Loading.

Feifei Jiang1, Shengzhi Liu2,3, Andy Chen2, Bai-Yan Li3, Alexander G Robling4, Jie Chen1, Hiroki Yokota1,2,4.   

Abstract

Breast cancer-associated bone metastasis induces bone loss, followed by an increased risk of bone fracture. To develop a strategy for preventing tumor growth and protecting bone, an understanding of the mechanical properties of bone under tumor burden is indispensable. Using a mouse model of mammary tumor, we conducted finite element analysis (FEA) of two bone samples from the distal femur. One sample was from a placebo-treated mouse, and the other was from a mouse treated with the investigational drug candidate, PD407824, an inhibitor of checkpoint kinases. Mechanical testing and microCT images revealed that bone strength is improved by administration of PD407824. In response to loading to the knee, FEA predicted that the peaks of von Mises stress, an indicator of fracture yielding, as well as the third principal compressive stress, were higher in the placebo-treated femur than the drug-treated femur. Higher peak stresses in trabecular segments were observed in the lateral condyle, a critical region for integrity of the knee joint. Collectively, this FE study supports the notion that mechanical weakening of the femur was observed in the tumor-invaded trabecular bone, and chemical agents such as PD407824 may potentially assist in preventing bone loss and bone fracture.

Entities:  

Keywords:  bone metastasis; distal femur; finite element analysis; knee loading

Year:  2018        PMID: 30505850      PMCID: PMC6261479     

Source DB:  PubMed          Journal:  Int J Orthop (Hong Kong)        ISSN: 2311-5106


  19 in total

Review 1.  Mechanisms of bone metastasis.

Authors:  G David Roodman
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

2.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Authors:  Catherine H Van Poznak; Sarah Temin; Gary C Yee; Nora A Janjan; William E Barlow; J Sybil Biermann; Linda D Bosserman; Cindy Geoghegan; Bruce E Hillner; Richard L Theriault; Dan S Zuckerman; Jamie H Von Roenn
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

3.  Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation.

Authors:  Christopher J Squire; James M Dickson; Ivan Ivanovic; Edward N Baker
Journal:  Structure       Date:  2005-04       Impact factor: 5.006

4.  Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).

Authors:  R E Coleman
Journal:  Breast Cancer       Date:  2000       Impact factor: 4.239

5.  CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers.

Authors:  F Bertoni; A M Codegoni; D Furlan; M G Tibiletti; C Capella; M Broggini
Journal:  Genes Chromosomes Cancer       Date:  1999-10       Impact factor: 5.006

6.  The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells.

Authors:  Hai Wang; Cuijuan Yu; Xia Gao; Thomas Welte; Aaron M Muscarella; Lin Tian; Hong Zhao; Zhen Zhao; Shiyu Du; Jianning Tao; Brendan Lee; Thomas F Westbrook; Stephen T C Wong; Xin Jin; Jeffrey M Rosen; C Kent Osborne; Xiang H-F Zhang
Journal:  Cancer Cell       Date:  2015-01-15       Impact factor: 31.743

7.  Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

Authors:  Robert Coleman; David Cameron; David Dodwell; Richard Bell; Caroline Wilson; Emma Rathbone; Maccon Keane; Miguel Gil; Roger Burkinshaw; Robert Grieve; Peter Barrett-Lee; Diana Ritchie; Victoria Liversedge; Samantha Hinsley; Helen Marshall
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

Review 8.  New insights into checkpoint kinase 1 in the DNA damage response signaling network.

Authors:  Yun Dai; Steven Grant
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

Review 9.  Targeting the ATR-CHK1 Axis in Cancer Therapy.

Authors:  Stuart Rundle; Alice Bradbury; Yvette Drew; Nicola J Curtin
Journal:  Cancers (Basel)       Date:  2017-04-27       Impact factor: 6.639

10.  Inhibiting checkpoint kinase 1 protects bone from bone resorption by mammary tumor in a mouse model.

Authors:  Shengzhi Liu; Yang Liu; Kazumasa Minami; Andy Chen; Qiaoqiao Wan; Yukun Yin; Liangying Gan; Aihua Xu; Nariaki Matsuura; Masahiko Koizumi; Yunlong Liu; Sungsoo Na; Jiliang Li; Harikrishna Nakshatri; Bai-Yan Li; Hiroki Yokota
Journal:  Oncotarget       Date:  2018-01-19
View more
  2 in total

1.  Finite-element analysis of the mouse proximal ulna in response to elbow loading.

Authors:  Feifei Jiang; Aydin Jalali; Chie Deguchi; Andy Chen; Shengzhi Liu; Rika Kondo; Kazumasa Minami; Takashi Horiuchi; Bai-Yan Li; Alexander G Robling; Jie Chen; Hiroki Yokota
Journal:  J Bone Miner Metab       Date:  2018-07-30       Impact factor: 2.626

2.  Temporal and spatial changes in bone mineral content and mechanical properties during breast-cancer bone metastases.

Authors:  Anneke S K Verbruggen; Elan C McCarthy; Roisin M Dwyer; Laoise M McNamara
Journal:  Bone Rep       Date:  2022-06-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.